ES2167561T3 - Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos. - Google Patents

Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.

Info

Publication number
ES2167561T3
ES2167561T3 ES96913954T ES96913954T ES2167561T3 ES 2167561 T3 ES2167561 T3 ES 2167561T3 ES 96913954 T ES96913954 T ES 96913954T ES 96913954 T ES96913954 T ES 96913954T ES 2167561 T3 ES2167561 T3 ES 2167561T3
Authority
ES
Spain
Prior art keywords
nucleic acid
acid molecules
molecula
complexed
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96913954T
Other languages
English (en)
Inventor
Yannick Guilloux
Francine Jotereau
Thierry Boon-Falleur
Sophie Lucas
Vincent Brichard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Institut National de la Sante et de la Recherche Medicale INSERM
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Institut National de la Sante et de la Recherche Medicale INSERM
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Institut National de la Sante et de la Recherche Medicale INSERM, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2167561T3 publication Critical patent/ES2167561T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCUBREN NUEVOS PRECURSORES DE ANTIGENO DE RECHAZO TUMORAL, Y LAS MOLECULAS DE ACIDO NUCLEICO QUE LOS CODIFICAN. ESTOS PRECURSORES DE ANTIGENO DE RECHAZO TUMORAL SE DEFINEN COMO PRECURSORES DE ANTIGENO DE RECHAZO DE TUMORES NAG, Y LAS MOLECULAS DE ACIDO NUCLEICO QUE LOS CODIFICAN SE DEFINEN COMO MOLECULAS CODIFICADORAS DE NAG. SE DESCRIBEN DIVERSOS USOS DIAGNOSTICOS Y TERAPEUTICOS DE LAS SECUENCIAS CODIFICANTES Y DE LAS MOLECULAS PRECURSORAS DE ANTIGENOS DE RECHAZO TUMORAL.
ES96913954T 1995-06-07 1996-05-07 Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos. Expired - Lifetime ES2167561T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/487,135 US5821122A (en) 1995-06-07 1995-06-07 Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof

Publications (1)

Publication Number Publication Date
ES2167561T3 true ES2167561T3 (es) 2002-05-16

Family

ID=23934549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96913954T Expired - Lifetime ES2167561T3 (es) 1995-06-07 1996-05-07 Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.

Country Status (12)

Country Link
US (3) US5821122A (es)
EP (1) EP0845032B1 (es)
JP (1) JP3849102B2 (es)
AT (1) ATE209680T1 (es)
AU (1) AU704934B2 (es)
CA (1) CA2223694C (es)
DE (1) DE69617440T2 (es)
DK (1) DK0845032T3 (es)
ES (1) ES2167561T3 (es)
PT (1) PT845032E (es)
WO (1) WO1996040039A2 (es)
ZA (1) ZA963907B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA98656B (en) 1997-01-27 1998-08-17 Ludwig Inst Cancer Res Lage-1 tumer associated nucleic acids
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US20020164654A1 (en) * 2000-01-20 2002-11-07 Rosalie Luiten MAGE antigenic peptides which bind HLA-B35 and HLA-B44
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN1268394C (zh) 2001-01-17 2006-08-09 特鲁比昂药品公司 结合域－免疫球蛋白融合蛋白
US6607151B2 (en) 2001-08-16 2003-08-19 Morris Samelson Ultra fine dead sea mineral compound and method of manufacture
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
EP1684801B1 (en) * 2003-11-21 2009-12-02 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
US20070026022A1 (en) * 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
KR20100092031A (ko) * 2004-06-17 2010-08-19 맨카인드 코포레이션 에피토프 유사체
US8188243B2 (en) * 2004-06-23 2012-05-29 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
WO2011032003A1 (en) 2009-09-10 2011-03-17 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
AU2013273987B2 (en) 2012-06-15 2018-08-09 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
KR20150132479A (ko) 2013-03-15 2015-11-25 어댑티브 바이오테크놀로지스 코포레이션 복합 유전자 세트에서의 독특하게 태그되고 재배열된 적응 면역 수용체 유전자
WO2015058111A1 (en) 2013-10-17 2015-04-23 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and thereapeutic agents
WO2015172153A1 (en) 2014-05-09 2015-11-12 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3512563A1 (en) 2016-09-16 2019-07-24 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
EP3615052B1 (en) 2017-04-27 2023-01-25 The University of Hong Kong Use of hcn inhibitors for treatment of cancer
WO2018237109A1 (en) 2017-06-23 2018-12-27 Yale University NANOMATERIALS HAVING IMPROVED MEDICATION DELIVERY EFFICIENCY
EP4377338A2 (en) 2021-07-27 2024-06-05 Novab, Inc. Engineered vlrb antibodies with immune effector functions
US20230172870A1 (en) 2021-12-08 2023-06-08 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues
WO2023147552A1 (en) 2022-01-28 2023-08-03 University Of Georgia Research Foundation, Inc. Radiosensitizing compositions and methods of use thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP0687180B1 (en) * 1992-12-22 2000-11-08 Ludwig Institute For Cancer Research Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules

Also Published As

Publication number Publication date
ZA963907B (en) 1997-03-11
US5821122A (en) 1998-10-13
EP0845032A2 (en) 1998-06-03
US5958711A (en) 1999-09-28
PT845032E (pt) 2002-05-31
DE69617440D1 (de) 2002-01-10
DK0845032T3 (da) 2002-05-06
AU5676996A (en) 1996-12-30
WO1996040039A3 (en) 2000-03-23
ATE209680T1 (de) 2001-12-15
EP0845032A4 (en) 2000-05-10
JP2001520506A (ja) 2001-10-30
AU704934B2 (en) 1999-05-06
US5886145A (en) 1999-03-23
CA2223694A1 (en) 1996-12-19
JP3849102B2 (ja) 2006-11-22
EP0845032B1 (en) 2001-11-28
WO1996040039A2 (en) 1996-12-19
DE69617440T2 (de) 2002-08-08
CA2223694C (en) 2003-06-24

Similar Documents

Publication Publication Date Title
ES2167561T3 (es) Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.
FI956019A (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
FI960268A (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
PT100515A (pt) Moleculas de acido nucleico, precursores de antigenios de rejeicao de tumores, antigenios da rejeicao de tumores e suas utilizacoes
DK0690675T3 (da) Nukleinsyre, der koder for en tumorafstödningsantigenprecursor
ES2192602T3 (es) Molecula de acido nucleico aislada y truncada, que codifica el antigeno de rechazo tumurall gage.
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
ATE134874T1 (de) Synoviale phospholipasen
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof